array:19 [
  "pii" => "X0211699502027693"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2002-04-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2002;22 Supl 2:48"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1736
    "formatos" => array:3 [
      "EPUB" => 194
      "HTML" => 1214
      "PDF" => 328
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699502027685"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2002-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2002;22 Supl 2:49-51"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3953
      "formatos" => array:3 [
        "EPUB" => 193
        "HTML" => 3277
        "PDF" => 483
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Blood presure control in dialysis patients: HD vs CAPD"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "49"
          "paginaFinal" => "51"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M. C. RIELLA"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "M. C. RIELLA"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027685?idApp=UINPBA000064"
    "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027685/v0_201502091327/en/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699502027708"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2002-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2002;22 Supl 2:46-7"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2974
      "formatos" => array:3 [
        "EPUB" => 203
        "HTML" => 1875
        "PDF" => 896
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "The HOPE (Heart Outcomes Prevention in Evaluation) trial"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "46"
          "paginaFinal" => "47"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "B. H. R. WOLFFENBUTTEL"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "B. H. R. WOLFFENBUTTEL"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027708?idApp=UINPBA000064"
    "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027708/v0_201502091327/en/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Cardiovascular prevention and blood pressure reduction: an overview of the outcome trials"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "48"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "J. A. STAESSEN , J. G. WANG , L. THIJS"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "J. A. STAESSEN , J. G. WANG , L. THIJS"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XXII. Suplemento 2. 2002 Cardiovascular prevention and blood pressure reduction: an overview of the outcome trials J. A. Staessen, J. G. Wang and L. Thijs Study Coordinating Centre. University of Leuven, B-3000 Leuven. Belgium. In a quantiative overview of published trials, we investigated whether pharmacological properties of antihypertensive drugs or reduction of SBP explain CV outcomes in hypertensive or high-risk patients. We extracted summary statistics from published articles and computed pooled odds ratios for experimental vs reference treatment from stratified 2 x 2 contingency tables after application of Zelen's test of heterogeneity. Using meta-regression, we correlated across trials odds ratios with differences in SBP between study groups. In 9 recent trials, 62 605 hypertensive patients were randomised to initial treatment with older or newer drugs. Compared with diuretics and -blockers, calcium-channel blockers and converting-enzyme inhibitors offered similar overall CV protection, but calcium-channel blockers provided more reduction in the risk of stroke (13.5%, 95% CI 1.3-24.2%, p = 0.03) and less reduction in the risk of MI (19.2%, 95% CI 3.5-37.3%, p = 0.01). Among these 9 trials, there was significant heterogeneity due to the higher risk of CV events on doxazosin in the ALLHAT trial and the higher risk of stroke on captopril in the CAPPP study. However, in these 2 trials, the difference in SBP between the randomised groups was 2-3 mmHg. Similar SBP differences occurred in the NORDIL trial (diltiazem vs older drugs) and in 3 other trials (HOPE, PART2 and SCAT) testing a converting-enzyme inhibitor against placebo in high-risk patients. Metaregression across 27 trials (136 124 patients) showed that the observed odds ratios could be explained in terms of the achieved differences in SBP between study groups except for the NORDIL trial, in which the risk of stroke was lower on diltiazem despite a 3.1 mmHg higher SBP. The finding that in the reviewed trials BP reduction largely accounted for outcome emphasizes the desirability of blood pressure control. On average, all current antihypertensive drugs have similar long-term efficacy and safety. Calciumchannel blockers may be particularly effective in preventing stroke. The hypothesis that convertingenzyme inhibitors or -blockers might influence CV prognosis over and beyond their antihypertensive effect remains unproved. 48 "
    "pdfFichero" => "P7-E193-S140-A3699.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027693/v0_201502091327/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000022000000S2/v0_201502091327/X0211699502027693/v0_201502091327/en/P7-E193-S140-A3699.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027693?idApp=UINPBA000064"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

Cardiovascular prevention and blood pressure reduction: an overview of the outcome trials
J. A. STAESSEN , J. G. WANG , L. THIJS
Leído
4297
Veces
se ha leído el artículo
1756
Total PDF
2541
Total HTML
Compartir estadísticas
 array:19 [
  "pii" => "X0211699502027693"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2002-04-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2002;22 Supl 2:48"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1736
    "formatos" => array:3 [
      "EPUB" => 194
      "HTML" => 1214
      "PDF" => 328
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699502027685"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2002-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2002;22 Supl 2:49-51"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3953
      "formatos" => array:3 [
        "EPUB" => 193
        "HTML" => 3277
        "PDF" => 483
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Blood presure control in dialysis patients: HD vs CAPD"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "49"
          "paginaFinal" => "51"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M. C. RIELLA"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "M. C. RIELLA"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027685?idApp=UINPBA000064"
    "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027685/v0_201502091327/en/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699502027708"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2002-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2002;22 Supl 2:46-7"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2974
      "formatos" => array:3 [
        "EPUB" => 203
        "HTML" => 1875
        "PDF" => 896
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "The HOPE (Heart Outcomes Prevention in Evaluation) trial"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "46"
          "paginaFinal" => "47"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "B. H. R. WOLFFENBUTTEL"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "B. H. R. WOLFFENBUTTEL"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027708?idApp=UINPBA000064"
    "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027708/v0_201502091327/en/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Cardiovascular prevention and blood pressure reduction: an overview of the outcome trials"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "48"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "J. A. STAESSEN , J. G. WANG , L. THIJS"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "J. A. STAESSEN , J. G. WANG , L. THIJS"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XXII. Suplemento 2. 2002 Cardiovascular prevention and blood pressure reduction: an overview of the outcome trials J. A. Staessen, J. G. Wang and L. Thijs Study Coordinating Centre. University of Leuven, B-3000 Leuven. Belgium. In a quantiative overview of published trials, we investigated whether pharmacological properties of antihypertensive drugs or reduction of SBP explain CV outcomes in hypertensive or high-risk patients. We extracted summary statistics from published articles and computed pooled odds ratios for experimental vs reference treatment from stratified 2 x 2 contingency tables after application of Zelen's test of heterogeneity. Using meta-regression, we correlated across trials odds ratios with differences in SBP between study groups. In 9 recent trials, 62 605 hypertensive patients were randomised to initial treatment with older or newer drugs. Compared with diuretics and -blockers, calcium-channel blockers and converting-enzyme inhibitors offered similar overall CV protection, but calcium-channel blockers provided more reduction in the risk of stroke (13.5%, 95% CI 1.3-24.2%, p = 0.03) and less reduction in the risk of MI (19.2%, 95% CI 3.5-37.3%, p = 0.01). Among these 9 trials, there was significant heterogeneity due to the higher risk of CV events on doxazosin in the ALLHAT trial and the higher risk of stroke on captopril in the CAPPP study. However, in these 2 trials, the difference in SBP between the randomised groups was 2-3 mmHg. Similar SBP differences occurred in the NORDIL trial (diltiazem vs older drugs) and in 3 other trials (HOPE, PART2 and SCAT) testing a converting-enzyme inhibitor against placebo in high-risk patients. Metaregression across 27 trials (136 124 patients) showed that the observed odds ratios could be explained in terms of the achieved differences in SBP between study groups except for the NORDIL trial, in which the risk of stroke was lower on diltiazem despite a 3.1 mmHg higher SBP. The finding that in the reviewed trials BP reduction largely accounted for outcome emphasizes the desirability of blood pressure control. On average, all current antihypertensive drugs have similar long-term efficacy and safety. Calciumchannel blockers may be particularly effective in preventing stroke. The hypothesis that convertingenzyme inhibitors or -blockers might influence CV prognosis over and beyond their antihypertensive effect remains unproved. 48 "
    "pdfFichero" => "P7-E193-S140-A3699.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027693/v0_201502091327/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000022000000S2/v0_201502091327/X0211699502027693/v0_201502091327/en/P7-E193-S140-A3699.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027693?idApp=UINPBA000064"
]
Información del artículo
ISSN: 02116995
Idioma original: Inglés
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 4 9 13
2024 Octubre 35 30 65
2024 Septiembre 25 22 47
2024 Agosto 61 53 114
2024 Julio 30 21 51
2024 Junio 34 34 68
2024 Mayo 66 28 94
2024 Abril 36 22 58
2024 Marzo 20 19 39
2024 Febrero 29 36 65
2024 Enero 17 22 39
2023 Diciembre 33 19 52
2023 Noviembre 19 33 52
2023 Octubre 22 32 54
2023 Septiembre 24 27 51
2023 Agosto 27 19 46
2023 Julio 23 25 48
2023 Junio 31 19 50
2023 Mayo 27 29 56
2023 Abril 13 16 29
2023 Marzo 15 25 40
2023 Febrero 17 23 40
2023 Enero 22 19 41
2022 Diciembre 22 32 54
2022 Noviembre 25 28 53
2022 Octubre 42 49 91
2022 Septiembre 24 33 57
2022 Agosto 28 50 78
2022 Julio 18 37 55
2022 Junio 18 28 46
2022 Mayo 20 32 52
2022 Abril 28 32 60
2022 Marzo 22 40 62
2022 Febrero 24 44 68
2022 Enero 25 39 64
2021 Diciembre 19 44 63
2021 Noviembre 24 34 58
2021 Octubre 29 34 63
2021 Septiembre 20 32 52
2021 Agosto 22 29 51
2021 Julio 18 28 46
2021 Junio 14 10 24
2021 Mayo 17 20 37
2021 Abril 20 18 38
2021 Marzo 23 10 33
2021 Febrero 33 7 40
2021 Enero 12 18 30
2020 Diciembre 11 12 23
2020 Noviembre 10 6 16
2020 Octubre 8 7 15
2020 Septiembre 8 9 17
2020 Agosto 18 11 29
2020 Julio 22 13 35
2020 Junio 16 11 27
2020 Mayo 10 18 28
2020 Abril 23 10 33
2020 Marzo 10 17 27
2020 Febrero 22 9 31
2020 Enero 25 18 43
2019 Diciembre 12 15 27
2019 Noviembre 16 7 23
2019 Octubre 3 4 7
2019 Septiembre 15 10 25
2019 Agosto 8 8 16
2019 Julio 14 14 28
2019 Junio 16 3 19
2019 Mayo 12 7 19
2019 Abril 38 26 64
2019 Marzo 15 12 27
2019 Febrero 6 10 16
2019 Enero 9 11 20
2018 Diciembre 20 20 40
2018 Noviembre 48 6 54
2018 Octubre 31 9 40
2018 Septiembre 23 6 29
2018 Agosto 11 8 19
2018 Julio 14 6 20
2018 Junio 12 9 21
2018 Mayo 14 10 24
2018 Abril 13 4 17
2018 Marzo 12 7 19
2018 Febrero 10 2 12
2018 Enero 10 5 15
2017 Diciembre 13 3 16
2017 Noviembre 9 6 15
2017 Octubre 10 3 13
2017 Septiembre 5 3 8
2017 Agosto 14 5 19
2017 Julio 12 7 19
2017 Junio 13 13 26
2017 Mayo 10 5 15
2017 Abril 4 2 6
2017 Marzo 8 7 15
2017 Febrero 13 3 16
2017 Enero 10 3 13
2016 Diciembre 15 7 22
2016 Noviembre 19 7 26
2016 Octubre 23 6 29
2016 Septiembre 21 5 26
2016 Agosto 53 1 54
2016 Julio 62 0 62
2016 Junio 49 0 49
2016 Mayo 76 0 76
2016 Abril 33 0 33
2016 Marzo 33 0 33
2016 Febrero 46 0 46
2016 Enero 35 0 35
2015 Diciembre 43 0 43
2015 Noviembre 36 0 36
2015 Octubre 27 0 27
2015 Septiembre 35 0 35
2015 Agosto 21 0 21
2015 Julio 28 0 28
2015 Junio 10 0 10
2015 Mayo 13 0 13
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Nefrología
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?